ABBV vs JNJ: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JNJ |
| Current Price |
$197.69 |
$230.69 |
| Fair Value Estimate |
$210.22 |
$255.61 |
| Upside to Fair Value |
+6.3%
|
+10.8%
|
| Market Cap |
$349.7B |
$555.9B |
| Forward P/E |
83.3x
|
26.8x
|
| EV / EBITDA |
23.4x
|
18.5x
|
| Price / Sales |
5.7x
|
5.8x
|
| Price / FCF |
18.7x
|
28.2x
|
| Revenue Growth YoY |
+10.0%
|
+9.9%
|
| Gross Margin |
70.2%
|
69.1%
|
| Operating Margin |
26.7%
|
26.9%
|
| Return on Equity |
-361.6%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.54%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
ABBV |
JNJ |
| Zone Low |
$157.66 |
$191.71 |
| Zone High |
$178.69 |
$217.27 |
| In Buy Zone? |
No
|
No
|